Avandia label gets tougher safety label
GlaxoSmithKline says it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack. Full story
GSK faces Q4 profit wipe-out on $3 billion legal hit
GlaxoSmithKline will record a legal charge of 2.2 billion pounds ($3.4 billion) for the fourth quarter, effectively wiping out its profit, as it settles further claims related to Avandia and sales practices. Full story
Diabetes pill Avandia to be severely restricted
U.S. government health regulators will allow GlaxoSmithKline to continue selling a controversial diabetes pill but will restrict access to the once-blockbuster drug because of heart attack risks. Full story
FDA to severely restrict access to Avandia
After a long-running controversy about Avandia's heart attack risk, the FDA put such tight restrictions on it that sales in this country are expected to plunge to nearly zero. Meanwhile, regulators in Europe say Avandia will no longer be available at all. NBC's Brian Williams reports.
FDA Votes for Avandia
US advisers say keep Glaxo's Avandia on the market, with Les Funtleyder, Miller Tabak Healthcare Strategist.
FDA issues mixed verdict on Avandia
The FDA on Wednesday recommended keeping the controversial diabetes drug Avandia on the market, but with new label revisions and significant sales restrictions. NBC's Robert Bazell reports.
Sponsored Links
Articles
Video
July 14: Nightly News Wednesday broadcast
OIL, Anne Thompson; DICK CHENEY, Jamie Gangel, Robert Bazell; AVANDIA, Robert Bazell; TOYOTA, Brian Williams; ECONOMY, Brian Williams; KANDAHAR ATTACK, Jim Maceda; TEXTING/PARENTING, Kevin Tibbles; VERNON BAKER 1919-2010, Brian Williams; SPIRIT/TSA, Brian Williams; CHICKEN AND EGG, Brian Williams; M
advertisement | ad info
Related Photos
Diabetes drug Avandia (?Joe Raedle / Getty Images file)
MIAMI - JULY 14: A bottle and pills of the diabetes drug, Avandia are seen on July 14, 2010 in Miami, Florida. European and American drug regulators announced September 23, 2010, that sales of GlaxoSmithKline PLC's diabetes drug, Avandia, will be heavily restricted in the United States and complet
